Table 1 Literature review with regard to therapeutic strategy and outcome of glomerulonephritis in patients with Sjögren’s syndrome

[10]

64

11

1.4

proteinuria, hematuria

MPGN

N/A

-

mPSL pulse + IVCY

> 6 months

remission

50

12

0.9

proteinuria, hematuria

MSGN

N/A

-

mPSL pulse + IVCY

> 6 months

remission

60

8

4.9

proteinuria, hematuria

MPGN

N/A

-

mPSL pulse + IVCY

> 6 months

ESRD

50

18

0.8

proteinuria, hematuria

MPGN

N/A

-

mPSL pulse + IVCY

> 6 months

remission

66

28

1

proteinuria

MSGN

N/A

-

mPSL pulse + AZA or CsA

N/A

remission

44

5

1.1

proteinuria, hematuria, RBC cast

MSGN

N/A

-

moderate to high dose PSL

N/A

amelioration

very good clinical and laboratory response

68

15

1.5

proteinuria

MSGN

N/A

-

moderate to high dose PSL

N/A

amelioration

very good clinical and laboratory response

53

17

6.2

proteinuria, hematuria, RBC cast

GN, IN

N/A

-

mPSL pulse + IVCY

> 6 months

ESRD

74

27

1.6

proteinuria

MPGN, IN

N/A

-

no treatment

13 years

death

developed lymphoma

53

10

1.1

proteinuria, hematuria

MSGN

N/A

-

RTX

N/A

remission

75

15

0.9

proteinuria, hematuria

MPGN

N/A

-

mPSL pulse + IVCY

> 6 months

remission

38

11

0.7

proteinuria, hematuria

MPGN

N/A

-

mPSL pulse + IVCY

< 2 months

remission

42

7

1

proteinuria, hematuria

MPGN

N/A

-

moderate to high dose PSL

<1 years

amelioration

very good clinical and laboratory response

39

10

1.5

proteinuria

MPGN

N/A

-

mPSL pulse + IVCY

< 2 months

remission

25

4

0.8

proteinuria

MPGN

N/A

-

moderate to high dose PSL

N/A

amelioration

very good clinical and laboratory response

42

12

1

proteinuria, hematuria

MPGN

N/A

+

R-CHOP

<1 years

stable

75

31

0.8

hematuria

MSGN, IN

N/A

-

no treatment

23 years

N/A

55

14

1.2

proteinuria, hematuria

MSGN, IN

N/A

+

chemotherapy without RTX

N/A

amelioration

43

15

1.5

normal finding

proliferative GN, IN

N/A

-

mPSL pulse + IVCY

<1 years

remission

59

8

0.9

hematuria

MN

N/A

-

moderate to high dose PSL

N/A

amelioration

65

8

0.9

proteinuria

MN

N/A

-

mPSL pulse + AZA or CsA

N/A

remission

[11]

N/A

7

2

proteinuria, hematuria

MPGN, IN

+

-

① moderate dose PSL + HCQ

① 24 months

① detelioration

② moderate dose PSL + RTX

② 5 months

② amelioration

N/A

0

1.6

proteinuria, hematuria

Fibrially GN

-

-

① high dose PSL

① 2.5 months

① detelioration

② moderate dose PSL + RTX

② 5 months

② detelioration

N/A

20

0.8

normal finding

MPGN

+

-

① moderate dose PSL + MMF

① 10 months

① stable

complication of vasculatic ulcers

② high dose PSL + oral CY

② 3 months

② stable

③ moderate dose PSL + MMF

③ 3 months

③ remission

N/A

11

0.9

proteinuria, hematuria

MPGN

+

-

① low dose PSL + HCQ + colchicine

① 4 years

① stable

② high dose PSL + MMF

② 12.5 months

② detelioration

③ moderate dose PSL + RTX

③ 6 months

③ remission

[12]

58

N/A

3.5

proteinuria

MPGN, IN

+

-

PSL

<1 months

amelioration

47

N/A

1.4

proteinuria, hematuria

MPGN, IN

+

-

PSL + HCQ, RTX added 12 years after

12 years

amelioration

developed lymphoma 12 years after diagnosis of GN